Pharma Giant AstraZeneca Takes China Probes
AstraZeneca chief says group takes China probe ‘very seriously’
AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of strong sales of cancer medicines.
AstraZeneca lifts 2024 outlook
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Andrew Berens gave his rating based on several factors, including AstraZeneca’s strong financial performance in the third quarter of 2024. The company reported total revenues of $13.565 billion, ...
LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
AstraZeneca's Q3 sales rose 18% YoY to $13.6 billion Adjusted EPADS hit $1.04, exceeding expectations. U.S. investment of ...
Full Year Guidance Upgrade (2024): Total revenue and core EPS expected to grow by high 10s percentage. AstraZeneca PLC ...
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback